News headlines about MEDNAX (NYSE:MD) have been trending somewhat positive on Monday, according to Accern Sentiment Analysis. Accern rates the sentiment of media coverage by analyzing more than twenty million blog and news sources in real time. Accern ranks coverage of public companies on a scale of -1 to 1, with scores nearest to one being the most favorable. MEDNAX earned a news impact score of 0.11 on Accern’s scale. Accern also gave media coverage about the company an impact score of 46.2546176878169 out of 100, meaning that recent media coverage is somewhat unlikely to have an impact on the stock’s share price in the next few days.
Several research firms recently commented on MD. Citigroup dropped their target price on MEDNAX from $52.00 to $47.00 and set a “neutral” rating for the company in a research note on Friday, November 3rd. Jefferies Group reiterated a “hold” rating and issued a $44.00 target price on shares of MEDNAX in a research note on Friday, November 3rd. Robert W. Baird upped their target price on MEDNAX from $47.00 to $48.00 and gave the company a “neutral” rating in a research note on Friday, November 3rd. KeyCorp raised MEDNAX from a “sector weight” rating to an “overweight” rating and set a $51.00 price target for the company in a research report on Sunday, September 17th. Finally, Zacks Investment Research raised MEDNAX from a “sell” rating to a “hold” rating in a research report on Wednesday, October 11th. Two investment analysts have rated the stock with a sell rating, ten have issued a hold rating and three have assigned a buy rating to the company. The stock has an average rating of “Hold” and an average target price of $53.82.
MEDNAX (NYSE:MD) traded down $1.02 during mid-day trading on Monday, reaching $53.48. The company’s stock had a trading volume of 1,190,585 shares, compared to its average volume of 1,003,200. MEDNAX has a 1 year low of $40.56 and a 1 year high of $72.13. The company has a debt-to-equity ratio of 0.62, a quick ratio of 1.37 and a current ratio of 1.37. The stock has a market capitalization of $5,104.21, a P/E ratio of 18.90, a PEG ratio of 1.64 and a beta of 0.39.
MEDNAX (NYSE:MD) last posted its quarterly earnings results on Wednesday, November 1st. The company reported $0.87 earnings per share (EPS) for the quarter, meeting the Zacks’ consensus estimate of $0.87. MEDNAX had a return on equity of 10.80% and a net margin of 7.76%. The firm had revenue of $868.95 million during the quarter, compared to the consensus estimate of $864.78 million. During the same quarter in the previous year, the business earned $1.09 earnings per share. The firm’s quarterly revenue was up 4.9% compared to the same quarter last year. equities analysts predict that MEDNAX will post 3.1 earnings per share for the current fiscal year.
In other news, insider John C. Pepia sold 3,000 shares of the company’s stock in a transaction dated Tuesday, December 12th. The stock was sold at an average price of $51.58, for a total value of $154,740.00. Following the completion of the sale, the insider now owns 35,569 shares of the company’s stock, valued at $1,834,649.02. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, Director Cesar L. Alvarez sold 10,668 shares of the company’s stock in a transaction dated Friday, November 3rd. The stock was sold at an average price of $42.59, for a total value of $454,350.12. Following the completion of the sale, the director now directly owns 44,215 shares of the company’s stock, valued at approximately $1,883,116.85. The disclosure for this sale can be found here. 2.40% of the stock is currently owned by insiders.
MEDNAX, Inc is a provider of physician services, including newborn, anesthesia, maternal-fetal, teleradiology, pediatric cardiology and other pediatric subspecialty care. As of December 31, 2016, the Company’s national network consisted of over 3,600 affiliated physicians, including over 1,130 physicians providing neonatal clinical care, in 35 states and Puerto Rico, primarily within hospital-based neonatal intensive care units (NICUs), to babies born prematurely or with medical complications.
Receive News & Ratings for MEDNAX Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MEDNAX and related companies with MarketBeat.com's FREE daily email newsletter.